Satellos lands FDA clearance and up to $5M grant for muscle-disease trial
What's the deal? Satellos BioscienceDealroom has a profile for this one. Try Dealroom → secured up to $5 million in non-dilutive milestone-based grant funding from the FSHD Canada Foundation, alongside US FDA clearance to study its lead drug in a second muscle disease. The Canadian clinical-stage company, listed on both the Nasdaq and TSX, develops medicines for degenerative muscle disorders.
The details: The FSHD Canada Foundation will provide the financing over the next five quarters to back forazapadin's program in facioscapulohumeral muscular dystrophy (FSHD). In exchange, the foundation receives a capped revenue-sharing interest in future FSHD-related proceeds.
Why now? The Food and Drug Administration cleared Satellos's Investigational New Drug application to test forazapadin in FSHD, a degenerative muscle disease with no approved therapies. It is the second such indication for the drug, which the company is also developing for Duchenne muscular dystrophy.
What's the endgame? Satellos plans to launch a Phase 2 randomised, double-blind, placebo-controlled proof-of-concept trial in adults with FSHD in the fourth quarter of 2026. The study will evaluate safety, tolerability, pharmacokinetics, and potential efficacy at 60mg and 120mg doses.
By the numbers: The financing structure adds cash without equity dilution — notable for a company with no revenue and ongoing losses. Satellos carries a market cap of US$197.3M, and analysts hold a Buy rating with a US$16.1 price target.
The signal: The grant ranks in the 91st percentile among health-sector grant rounds in Canada, a sizeable non-dilutive haul for a niche rare-disease developer. It reflects how patient advocacy groups are increasingly funding drug programs directly, sharing risk with biotechs targeting conditions where no approved treatments exist.
Read more: tipranks.com
Image credit: Satellos Bioscience
